ImmunityBio (IBRX) EBT (2014 - 2026)

ImmunityBio (IBRX) has 13 years of EBT data on file, last reported at -$632.8 million in Q1 2026.

• On a quarterly basis, EBT fell 387.13% year-over-year to -$632.8 million in Q1 2026; TTM through Mar 2026 was -$854.5 million, a 108.71% decrease from a year earlier, with the FY2025 full-year figure at -$351.6 million, up 15.0% from the prior year.
• EBT for Q1 2026 stood at -$632.8 million, down from -$62.1 million in the prior quarter.
• Over the last five years, EBT for IBRX reached as high as -$59.2 million in Q4 2024 and fell as low as -$632.8 million in Q1 2026.
• Historically, EBT has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Across the five-year window, EBT soared 74.65% in 2024 and tumbled 387.13% in 2026, its largest moves.
• Year by year, EBT stood at -$108.3 million in 2022, then sank by 115.58% to -$233.5 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then retreated by 4.92% to -$62.1 million in 2025, then sank by 919.1% to -$632.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$632.8 million in Q1 2026, -$62.1 million in Q4 2025, and -$67.3 million in Q3 2025.